COR-1389, a long-acting selective CRF-2 receptor agonist, in HFpEF with pulmonary hypertension due to left-heart disease: phase 1b randomised trial using wireless pulmonary artery pressure monitoring

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Professor Marcin Ufnal

Medical University of Warsaw, Warsaw (Poland)

4 More presentations in this session

Presentation thumbnail

Cardiac glycosides in heart failure with reduced ejection fraction in the era of contemporary guideline-directed medical therapy: a systematic review and meta-analysis

Doctor B. Lage Garcia (Guimaraes, PT)

Abstract Slides

Presentation thumbnail

Asymptomatic LV dysfunction in individuals with markedly increased coronary artery calcium: baseline CMR findings from EARLY-SYNERGY

Doctor T. Severijn (Utrecht, NL)

Abstract Slides

Presentation thumbnail

Longitudinal patterns of guideline-directed medical therapy use in severe heart failure with reduced ejection fraction after hospitalization: insights from the CONNECT-HF trial

Doctor P. Rambarat (Durham, US)

Abstract Slides

Presentation thumbnail

Dysregulated myocardial water balance and adverse outcomes in heart failure with preserved ejection fraction: insights from the NETDiamond cohort CMR substudy

Doctor F. Vasques-Novoa (Porto, PT)

Abstract Slides

Access the full session

Session thumbnail

Key insights from heart failure trials

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Session

Clinical phenotypes of heart failure with preserved ejection fraction

Congress Presentation

Mitral regurgitation, atrial fibrillation, and HFpEF: a three-headed dragon

Webinar

Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources